Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress Read More
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc. Read More
Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More
Oncolytics President and CEO Dr. Matt Coffey featured on @wallstanalyzer.
Listen to the interview here https://t.co/jyXO09gYRb. #TSX $ONC
Zacks Analyst @vanjohn10 talks #capital and valuation in #biotech—hear what he has to say about $ONC at 4:35. https://t.co/rxkFQSACBc